 |
Top 10 Atherosclerosis treatment startups
Updated: May 01, 2024 | Editor: Jason Kwon |
These startups develop new diagnostics and treatment technologies for Atherosclerosis and vascular disease, like AI-powered diagnostics, stem cells, 3D-bioprinting, nano-robots, new drugs...
1
Country: USA | Funding: $3B
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
2
Country: USA | Funding: $692.9M
Humacyte develops novel human tissue-based investigational products for potential applications in regenerative medicine and vascular surgery. The company uses a proprietary technology platform to isolate and grow stable, “off-the shelf” investigational human tissue replacements that, if approved, could be tailored to pre-designed clinical and commercial specifications.
Humacyte develops novel human tissue-based investigational products for potential applications in regenerative medicine and vascular surgery. The company uses a proprietary technology platform to isolate and grow stable, “off-the shelf” investigational human tissue replacements that, if approved, could be tailored to pre-designed clinical and commercial specifications.
3
Country: USA | Funding: $368.4M
HealthCheck Diagnostics seeks to reduce mortality in CAD and atherosclerosis patients with breakthrough biomarker testing that reveals cardiovascular disease and likely heart attacks through a non-invasive procedure.
HealthCheck Diagnostics seeks to reduce mortality in CAD and atherosclerosis patients with breakthrough biomarker testing that reveals cardiovascular disease and likely heart attacks through a non-invasive procedure.
4
Country: USA | Funding: $337.3M
CardioDx is a cardiovascular genomic diagnostics company located in Redwood City, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
CardioDx is a cardiovascular genomic diagnostics company located in Redwood City, CA. CardioDx develops clinically validated genomic tests to aid in assessing and tailoring care of individuals with cardiovascular disease, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure.
5
Country: USA | Funding: $316.1M
Avinger designs, develops and manufactures precision medical device technology to fight Peripheral Artery Disease and help patients keep their legs.
Avinger designs, develops and manufactures precision medical device technology to fight Peripheral Artery Disease and help patients keep their legs.
6
Country: Canada | Funding: $292.6M
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
7
Country: USA | Funding: $250M
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for high-risk cardiovascular patients.
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for high-risk cardiovascular patients.
8
Country: USA | Funding: $145.4M
Intact Vascular is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack Endovascular System is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease.
Intact Vascular is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack Endovascular System is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease.
9
Country: USA | Funding: $135.5M
The Cour particle platforms provide a novel and highly specific immune targeting capability which may be safely applied to severe inflammatory modulation, and immune (antigen) tolerization.
The Cour particle platforms provide a novel and highly specific immune targeting capability which may be safely applied to severe inflammatory modulation, and immune (antigen) tolerization.
10
Country: USA | Funding: $129.7M
Elucid enables precision medicine for cardiovascular disease by applying A.I to medical image analysis validated against true biology.
Elucid enables precision medicine for cardiovascular disease by applying A.I to medical image analysis validated against true biology.
11
Country: USA | Funding: $98M
MyoKardia is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure
MyoKardia is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure
12
Country: Switzerland | Funding: $87.1M
Genkyotex is the leading developer of NOX inhibitors. We are developing first-in-class, small molecule therapeutics that selectively inhibit NOX enzymes. NOX enzymes are key drivers in multiple diseases including fibrotic, inflammatory, cardiovascular and CNS diseases and oncology.
Genkyotex is the leading developer of NOX inhibitors. We are developing first-in-class, small molecule therapeutics that selectively inhibit NOX enzymes. NOX enzymes are key drivers in multiple diseases including fibrotic, inflammatory, cardiovascular and CNS diseases and oncology.
13
Country: USA | Funding: $80.9M
Profusa’s mission is to make our body’s chemistry easily accessible to improve health and wellness. We are dedicated to becoming a leader in the development of real-time biosensors that provide unprecedented insights into our overall health status.
Profusa’s mission is to make our body’s chemistry easily accessible to improve health and wellness. We are dedicated to becoming a leader in the development of real-time biosensors that provide unprecedented insights into our overall health status.
14
Country: Austria | Funding: $57,5m
AFFiRiS develops first-in-class antigen specific immunotherapies for the prevention and treatment of chronic illnesses on the basis of our proprietary AFFITOME technology. We have a conviction that active immunization can play a major role in prevention and therapy of chronic civilization illnesses such as Atherosclerosis, Diabetes or Neurodegenerative Diseases.
AFFiRiS develops first-in-class antigen specific immunotherapies for the prevention and treatment of chronic illnesses on the basis of our proprietary AFFITOME technology. We have a conviction that active immunization can play a major role in prevention and therapy of chronic civilization illnesses such as Atherosclerosis, Diabetes or Neurodegenerative Diseases.
15
Country: USA | Funding: $17.5M
Underdog develops easy-to-use drugs that prevent common age-related conditions such as atherosclerosis, heart-attack and stroke by addressing the root cause - a build-up of arterial plaque.
Underdog develops easy-to-use drugs that prevent common age-related conditions such as atherosclerosis, heart-attack and stroke by addressing the root cause - a build-up of arterial plaque.
16
Country: USA | Funding: $10.7M
AUM Cardiovascular’s vision is to reduce needless death due to coronary artery disease. Diagnose obstructive coronary artery disease in patients presenting with chest pain and two or more risk factors.
AUM Cardiovascular’s vision is to reduce needless death due to coronary artery disease. Diagnose obstructive coronary artery disease in patients presenting with chest pain and two or more risk factors.
17
Country: USA | Funding: $11M
Prevencio, a life science company, is a pioneer in multi-protein in vitro diagnostic (IVD) and prognostic tests for cardiovascular disease for use in Emergency Rooms (ER), cardiology clinics, and clinical laboratories
Prevencio, a life science company, is a pioneer in multi-protein in vitro diagnostic (IVD) and prognostic tests for cardiovascular disease for use in Emergency Rooms (ER), cardiology clinics, and clinical laboratories
18
Country: USA
Angionetics is focused on the late-stage clinical development and commercialization of Generx, an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.
Angionetics is focused on the late-stage clinical development and commercialization of Generx, an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.
19
Country: USA
Flow MedTech is a Health Wildcatters portfolio company developing an innovative therapy to reduce the chance of strokes in patients with atrial fibrillation by preventing clot formation in the left atrial appendage. The aim of the company is to design, develop, and commercialize novel catheter-based devices to reduce stroke risk.
Flow MedTech is a Health Wildcatters portfolio company developing an innovative therapy to reduce the chance of strokes in patients with atrial fibrillation by preventing clot formation in the left atrial appendage. The aim of the company is to design, develop, and commercialize novel catheter-based devices to reduce stroke risk.
20
Country: USA | Funding: $300K
International Cardio Corporation develops a technology that can treat atherosclerosis in a noninvasive manner that is faster, more precise and safer for the patient.
International Cardio Corporation develops a technology that can treat atherosclerosis in a noninvasive manner that is faster, more precise and safer for the patient.
21
Country: Singapore | Funding: SDG620K
QT Vascular is a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease.
QT Vascular is a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease.
